Amgen's Repatha linked to 29% lower cardiovascular event risk in long-term analysis
AMGN•A long-term analysis linked Amgen's Repatha to a 29% lower risk of major cardiovascular events versus a nonrandomized external control in patients with atherosclerotic cardiovascular disease. Other analyses found Repatha highly cost-effective for high-risk patients and reported fewer cardiovascular events and deaths among patients with chronic kidney disease who had no prior heart attack or stroke.
1. Long-term findings
A long-term FOURIER analysis linked Repatha to fewer major cardiovascular events than a nonrandomized external control among patients with atherosclerotic cardiovascular disease. Amgen presented the findings at the American Heart Association Scientific Sessions 2026.
2. Other analyses
An independent VESALIUS-CV economic analysis found Repatha highly cost-effective for high-risk patients without a prior heart attack or stroke. A separate VESALIUS-CV analysis found fewer cardiovascular events and deaths in patients with chronic kidney disease who had no prior heart attack or stroke.
